CYBIN CEO Michael Halstead will participate in a fireside chat at the Cantor Global Healthcare Conference on September 11, with a live webcast and replay available. The event gives investors direct access to management while CYBIN develops HLP003 in Phase 3 and HLP004 in Phase 2 clinical development.
Key Highlights
- Helus Pharma is developing HLP003 in Phase 3 and HLP004 in Phase 2 clinical development.
- Helus Pharma’s CEO will represent the company in a fireside chat at the Cantor Conference in New York City, taking place September 9 through September 11, 2026.
- The event will be webcast live, with registration available, and a replay will be posted through Helus Pharma’s Investor relations events and presentations page.
- HLP004 is in Phase 2 clinical development for generalized anxiety disorder, while regulators have not evaluated claims concerning NSAs, HLP003, or HLP004.
The event will be webcast live, and a replay will be available through Helus Pharma’s investor relations events and presentations page.
CEO Appearance Set for Cantor Conference
The conference is taking place in New York City from September 9 through September 11, 2026. Helus Pharma said its chief executive will represent the Business during the fireside chat, with registration available for the webcast. Helus Pharma is the commercial operating name of CYBIN INC. (NASDAQ: HELP) The clinical-stage pharmaceutical company is developing proprietary novel serotonergic agonists, or NSAs, described as synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. HLP004 is in Phase 2 clinical development for generalized anxiety disorder. The release states that regulators have not evaluated claims concerning NSAs, HLP003 or HLP004, and that the products’ efficacy has not been confirmed by approved research.
FAQs
Q: Will investors be able to watch the CYBIN conference appearance?
A: Helus Pharma plans to webcast the fireside chat live. A replay will also be posted on the company’s investor relations events and presentations page.
Q: What clinical programs is CYBIN developing?
A: CYBIN is developing HLP003 in Phase 3 clinical development for adjunctive treatment of major depressive disorder. HLP004 is in Phase 2 development for generalized anxiety disorder.
Q: When and where will the CEO appear?
A: The CEO is scheduled to represent Helus Pharma during a fireside chat at the Cantor Conference. The conference will take place in New York City from September 9 through September 11, 2026.
Q: How can investors access the event?
A: The event will be webcast live, and registration is available for the webcast. A replay will be available through Helus Pharma’s investor relations events and presentations page.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.